Zepbound Is Back on CVS Caremark in 2026: What the October 1 Coverage Change Means for You

CVS Caremark announced the reversal on May 28, 2026, laying out a two-step timeline: Eli Lilly's oral GLP-1 pill Foundayo (orforglipron) came off the new-to-market block on June 1, 2026, and Zepbound returned as a preferred option on employer-sponsored template formularies effective October 1, 2026. That second date just arrived, which means the change is now live for participating plans.

The practical upshot is that Zepbound and Wegovy are now co-preferred on CVS Caremark's standard commercial formularies: both sit on the same formulary tier, with comparable copay or coinsurance treatment for plans that adopt the template. Patients and their providers can choose between the two leading injectable GLP-1 medications based on clinical fit rather than on which drug the pharmacy benefit manager struck a deal with that year.

Industry analysts also note the bigger picture: with this change, Lilly's obesity medications are now available through all three of the largest US pharmacy benefit managers, which meaningfully expands the number of patients who can get Zepbound or Foundayo through insurance rather than paying cash.

On July 1, 2025, CVS Caremark removed Zepbound from its standard commercial formularies as part of a deal that gave Novo Nordisk's Wegovy preferred exclusivity. Roughly 200,000 patients reportedly lost Zepbound coverage and were told to switch to Wegovy, and the move drew sustained criticism from patients and clinicians — including a class-action lawsuit filed on behalf of patients who lost coverage through their employer plans.

The backlash reflected a real clinical concern. Zepbound and Wegovy are both effective, but they are not interchangeable for every patient: head-to-head and cross-trial data have generally favored tirzepatide for average weight loss, and some patients who respond well to one medication tolerate the other poorly. Forcing stable patients to switch mid-treatment put many of them through new side effects, new titration schedules, and in some cases weight regain. If you want to dig into how the two drugs compare on results, our breakdown of Zepbound versus high-dose Wegovy covers the current data in detail.

Before you assume your copay changes this week, three caveats matter.

First, employers have the final say. CVS Caremark's template formulary is the default, but individual employers can customize their plan and some exclude weight loss medications entirely. Zepbound being "preferred" on the template does not guarantee your specific plan adopted it, so the only way to know is to check your plan documents on caremark.com or call the member services number on your card.

Second, prior authorization has not gone away. Both Zepbound and Wegovy still typically require your provider to document that you meet clinical criteria — generally a BMI of 30 or higher, or 27 or higher with a weight-related condition. If you were switched from Zepbound to Wegovy last year, be aware that your old Zepbound authorization was not held in reserve; switching back will usually mean a fresh prior authorization request from your provider.

Third, a formulary position is not a price. Preferred status usually means a lower copay tier, but what you actually pay depends on your plan design and deductible. Medicare patients are on a separate track entirely — if that is you, our guide to the Medicare $50 GLP-1 bridge program explains the current rules.

If you are currently on Wegovy and doing well — losing or maintaining weight with manageable side effects — there is no medical reason to switch just because the formulary changed. Staying the course is often the right call, and that decision belongs in a conversation with your provider.

If you were switched off Zepbound involuntarily, or you are starting treatment for the first time, the path looks like this: confirm with your plan that Zepbound is covered at the preferred tier, then have your provider submit (or resubmit) prior authorization, and plan for the usual dose titration if you are starting fresh. Like all GLP-1 medications, tirzepatide commonly causes nausea, vomiting, diarrhea, or constipation, especially during dose increases — manageable for most patients, and prescription anti-nausea support can help during titration. GLP-1 medications are not appropriate for everyone: they should not be used during pregnancy, and anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not take them. A licensed provider should review your full history before you start.

Not every employer will adopt the change, and plenty of plans still exclude weight loss drugs altogether. If that is your situation, you still have options. Lilly's Foundayo pill joined CVS Caremark formularies back in June and may be covered even where injectables are not. Manufacturer self-pay programs have brought cash prices down substantially from list price. And telehealth-based treatment — including compounded tirzepatide programs like Tirz HD where clinically appropriate — can offer a predictable monthly cost without the insurance maze. The right choice depends on your budget, your health history, and your goals, which is exactly what a provider consultation is for.

Coverage news is only useful if it turns into treatment that works for you. JoeyMed's licensed providers can evaluate whether a GLP-1 medication is a good fit, help you navigate prior authorization now that Zepbound is back on preferred formularies, and offer transparent self-pay options if your insurance still will not cooperate. Everything happens online, with medications shipped discreetly to your door and ongoing provider support as your dose changes. Start your free online visit at JoeyMed Weight Loss today — a few minutes now could be the difference between waiting on your plan and actually starting your program this month.